Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in …

F Maloisel, A Guerci, D Guyotat, N Ifrah, M Michallet… - Leukemia, 2002 - nature.com
Cytarabine ocfosfate (YNK01) is a prodrug analogue of cytarabine which is resistant to
systemic deamination after oral administration. Following initial studies indicating significant …
被引用次数：24 相关文章
[PDF] academia.edu

[PDF][PDF] Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon-2b for the treatment of chronic myelogenous leukemia patients in …

F Maloisel, A Guerci, D Guyotat, N Ifrah, M Michallet… - Leukemia, 2002 - academia.edu
Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon
-2b for the treatment of chroni Page 1 Leukemia (2002) 16, 573–580 © 2002 Nature Publishing …

[引用][C] Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients …

F MALOISEL, A GUERCI, JF ABGRALL… - …, 2002 - pascal-francis.inist.fr
Author MALOISEL, F 1; GUERCI, A 2; ABGRALL, J. F 11; PEGOURIE-BANDELIER, B 12;
SOLARY, E 13; CAMBIER, N 14; COSO, D 15; VILQUE, J. P 16; DELAIN, M; HAROUSSEAU …

Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in …

F Maloisel, A Guerci, D Guyotat, N Ifrah, M Michallet… - Leukemia, 2002 - europepmc.org
Cytarabine ocfosfate (YNK01) is a prodrug analogue of cytarabine which is resistant to
systemic deamination after oral administration. Following initial studies indicating significant …

Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon [alpha]-2b for the treatment of chronic myelogenous leukemia patients in …

F Maloisel, A Guerci, D Guyotat, N Ifrah, M Michallet… - Leukemia, 2002 - go.gale.com
Cytarabine ocfosfate (YNK01) is a prodrug analogue of cytarabine which is resistant to
systemic deamination after oral administration. Following initial studies indicating significant …

Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in …

F Maloisel, A Guerci, D Guyotat, N Ifrah, M Michallet… - Leukemia, 2002 - hero.epa.gov
Cytarabine ocfosfate (YNK01) is a prodrug analogue of cytarabine which is resistant to
systemic deamination after oral administration. Following initial studies indicating significant …

Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in …

F Maloisel, A Guerci, D Guyotat, N Ifrah… - …, 2002 - pubmed.ncbi.nlm.nih.gov
Cytarabine ocfosfate (YNK01) is a prodrug analogue of cytarabine which is resistant to
systemic deamination after oral administration. Following initial studies indicating significant …
[PDF] researchgate.net

[PDF][PDF] Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon-2b for the treatment of chronic myelogenous leukemia patients in …

F Maloisel, A Guerci, D Guyotat, N Ifrah, M Michallet… - Leukemia, 2002 - researchgate.net
Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon
-2b for the treatment of chroni Page 1 Leukemia (2002) 16, 573–580  2002 Nature Publishing …

[引用][C] Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients …

F MALOISEL, A GUERCI, D GUYOTAT… - …, 2002 - Nature Publishing Group

[引用][C] Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon [alpha]-2b for the treatment of chronic myelogenous leukemia …

F Maloisel, A Guerci, D Guyotat, N Ifrah… - …, 2002 - Nature Publishing Group